MA-SES-AI
SES AI Corporation (“SES AI”) (NYSE: SES), a global leader in the development and manufacturing of high-performance Li-Metal batteries, today announced that it completed the conversion and Field Acceptance Test (FAT) of its Li-Metal cell production facility dedicated to Urban Air Mobility UAM in Chungju, South Korea – marking another step forward in the company’s commercialization of its Li-Metal battery technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240812943673/en/
(Graphic: Business Wire)
The completion of this line conversion and FAT is the world’s first high-energy density Li-Metal line dedicated to UAM applications. The facility will also have AI for Manufacturing and AI for Safety installed. SES AI has been working with its UAM partners on new cell design and converting its previous EV A-sample line to a UAM line since it first announced UAM as an exciting, new strategic market that complements its EV efforts in 2023.
“We have always been excited about the application of UAM for Li-Metal as a positive step towards commercialization. Our customers have been waiting for a production line dedicated to high-energy density Li-Metal,” said Qichao Hu, Founder and CEO of SES AI. “This UAM line comes at a perfect time, and together with the GB38031-2020 certification that we received for abuse safety, along with the AI for Safety that we are installing for in-use safety, our UAM customers can look forward to a new battery that’s both high energy density and safe.”
In December, SES AI announced UAM as a new exciting market in addition to EV. In April, SES AI advanced to the next phase of its joint development with Hyundai Motor Company and Kia Corporation by signing an agreement to develop B samples, making it the only Li-Metal battery company with two automotive B-sample agreements in progress and the world’s first Li-Metal line dedicated to UAM. Building on this momentum, during the recent Q2 shareholder meeting, the Company unveiled its All-in-one AI strategy, leveraging AI for Science, Manufacturing, and Safety to accelerate the commercialization of Li-Metal batteries.
About SES AI:
SES AI Corp. (NYSE: SES) is powering the future of global electric transportation on land and in the air with the world’s most advanced Li-Metal batteries. SES AI is the first battery company in the world to accelerate its pace of innovation by utilizing superintelligent AI across the spectrum of its business, from research and development; materials sourcing; cell design; engineering and manufacturing; to battery health and safety monitoring. Founded in 2012, SES AI is an Li-Metal battery developer and manufacturer headquartered in Boston and with operations in Singapore, Shanghai, and Seoul. Learn more at SES.AI.
SES AI may use its website as a distribution channel of material company information. Financial and other important information regarding SES AI is routinely posted on and accessible through the Company’s website at www.ses.ai. Accordingly, investors should monitor this channel, in addition to following SES AI’s press releases, Securities and Exchange Commission filings and public conference calls and webcasts.
Forward-Looking Statements
This press release contains statements that SES AI believes are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements relating to expectations for future financial performance, business strategies or expectations for our business. These statements are based on the beliefs and assumptions of the management of SES AI. Although SES AI believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, it cannot provide assurance that it will achieve or realize these plans, intentions or expectations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this press release, words such as “anticipate”, “believe”, “can”, “continue”, “could”, “estimate”, “expect”, “forecast”, “intend”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “seek”, “should”, “strive”, “target”, “will”, “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
You should not place undue reliance on these forward-looking statements. Should one or more of a number of known and unknown risks and uncertainties materialize, or should any of SES AI’s assumptions prove incorrect, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include, but are not limited to the following risks: risks related to the development and commercialization of SES AI’s battery technology and the timing and achievement of expected business milestones; risks relating to the uncertainty of achieving and maintaining profitability; risks relating to the uncertainty of meeting future capital requirements; the ability of SES to integrate its products into electric vehicles (“EVs”) and Urban Air Mobility (“UAM"), drones and other applications; the risk that delays in the pre-manufacturing development of SES AI’s battery cells could adversely affect SES AI’s business and prospects; the market for air mobility, and for use of Li-Metal technology in air mobility applications, is still emerging and may not achieve the growth potential we expect; risks relating to the development of the UAM market and demand for batteries from the UAM industry; potential supply chain difficulties; the ability of SES AI to engage target original equipment manufacturers (“OEMs”) customers successfully and integrate SES AI’s products into EVs manufactured by OEM customers; the ability to obtain raw materials, components or equipment through new or existing supply relationships; our use of artificial intelligence and machine learning may result in legal and regulatory risk; risks resulting from SES AI’s joint development agreements and other strategic alliances and investments; product liability and other potential litigation, regulation and legal compliance; SES AI’s ability to attract, train and retain highly skilled employees and key personnel; developments in alternative technology or other fossil fuel alternatives; risks related to SES AI’s intellectual property; business, regulatory, political, operational, financial and economic risks related to SES AI’s business operations outside the United States; SES AI has identified material weaknesses in its internal control over financial reporting and may identify material weaknesses in the future or otherwise fail to develop or maintain an effective system of internal controls; the volatility of SES AI’s common stock and value of SES AI’s public warrants; and the other risks described in “Part I, Item 1A. Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on February 27, 2024 and other documents filed from time to time with the SEC. There may be additional risks that SES AI presently knows and/or believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect SES AI’s expectations, plans or forecasts of future events and views only as of the date of this press release. SES AI anticipates that subsequent events and developments will cause its assessments to change. However, while SES AI may elect to update these forward-looking statements at some point in the future, SES AI specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing SES AI’s assessments as of any date subsequent to the date of this press release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812943673/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai to Host Dubai Woodshow’s 21st Edition, from April 14th to 16th, 202516.9.2024 08:30:00 CEST | Press release
Dubai is gearing up to host the 21st edition of Dubai Woodshow, the premier international trade fair focusing on the wood, furniture, and woodworking machinery industries in the MENA region (Middle East and North Africa), gathering more than 600 exhibitors from +50 countries around the world. Scheduled from April 14 to 16 at the Dubai World Trade Centre, the prestigious event will bring together industry professionals, manufacturers, suppliers and wood machinery and tools specialists, to showcase the latest products, services and technologies in the industry. It will also provide an exciting platform to display a wide variety of wood and woodworking machinery and tools, attracting international investors and businessmen to the region, which contributes to driving economic diversification and industrial advancement. Dubai WoodShow offers exhibitors the opportunity to connect with their existing customers and discuss prospects and possible synergies to expand their business, while identi
Curatis: Significantly Increased Sales in Core Business and Projects in Development Pipeline on Track16.9.2024 08:20:00 CEST | Press release
Curatis Holding (SIX:CURN) reports revenues of CHF 2.0m for H1 2024, whereby Curatis AG is only included for 2 months. Curatis AG was able to increase sales in the distribution business by 31% per cent to CHF 4.3m in the entire 6 months of 2024 compared to the first 6 months of 2023. The loss amounted to CHF 3.8m due to non-cash one-off effects and amortisation as well as transaction costs for the acquisition of Curatis AG. Cash flow, including one-time transaction costs for the business combination of over CHF 1 million, was CHF -0.7m. As planned, Curatis also submitted the orphan drug designation application for its lead product candidate C-PBTE-01 to the US Food and Drug Administration (FDA) and expects a response from the FDA in Q4 2024. Business development and finances Product sales in the first half of the year amounted to CHF 1.75m and services revenues to CHF0.23m, whereby Curatis AG, which was acquired on 26 April 2024, is only included in this figure for 2 months. Curatis AG
International ID Day: Thales Stands up for a Legal and Trusted Identity for Everyone16.9.2024 08:00:00 CEST | Press release
On the International Identity Day ‘ID Day’, Thales reaffirms its dedication to supporting global identity initiatives and driving technological advancements that foster inclusion, security, and trust. Around the world, more than 850 million individuals do not have a legal identity, preventing them from claiming their rights and accessing fundamental citizen services e.g. health, education, employment. Thales has been working for more than thirty years to make trustworthy identities a reality for everyone, employing cutting-edge and responsible technology for biometrics and digital ID solutions. On September 16th, Thales celebrates the International Identity Day (ID Day), a symbolic day to highlight the United Nations' Sustainable Development Goal16.9 to provide a legal identity for all. ID Day is dedicated to raising awareness about the importance of legal identity as a fundamental human right and a key enabler of inclusive social and economic development. Thales supports global effort
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer14.9.2024 18:45:00 CEST | Press release
New antitumor response data from a range of doses and regimens unveiled today at Incyte investor eventThese results build upon safety and tolerability data presented earlier today during a mini-oral presentation at the European Society of Medical Oncology (ESMO) Congress 2024Findings support the initiation of a pivotal trial in ovarian cancer, expected to begin in 2025; additional plans to evaluate INCB123667 in combination with other treatments are underway Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced solid tumors. The trial results, presented during a mini-oral presentation at the European Society of Medical Oncology (ESMO) with new, updated data shared during the Company’s investor event, highlight the potential of INCB123667 as a differentiated treatment option for cancers with increased Cyclin E1 activity, amplification and/or overexpression in cells predictive of
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium14.9.2024 16:30:00 CEST | Press release
- Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secondary endpoints in patients with squamous cell anal carcinoma (SCAC) taking retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) - Late-breaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024 support the planned U.S. filing of a supplemental Biologics License Application (sBLA) for retifanlimab in SCAC by year-end 2024 - Incyte to host an in-person analyst and investor event to review key data at ESMO on Saturday, September 14, 2024 from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST) Incyte (Nasdaq:INCY) today announced results from the Phase 3 POD1UM-303/InterAACT2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with platinum-based chemotherapy (carboplatin–paclitaxel) for the treatment of adults with inoperable locally recu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom